These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 1319447

  • 1. [The new heparins].
    Samama M, Babinet-Berthier A.
    J Mal Vasc; 1992; 17(2):91-106. PubMed ID: 1319447
    [Abstract] [Full Text] [Related]

  • 2. [Therapeutic indications of low molecular weight heparins].
    Samama MM, Michaut-Paterno F.
    Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1733-43. PubMed ID: 1662941
    [Abstract] [Full Text] [Related]

  • 3. [Treatment of venous thrombosis with low molecular weight heparin. Progress and outlook].
    Fiessinger JN.
    Bull Acad Natl Med; 1997 May; 181(5):875-83; discussion 883-5. PubMed ID: 9312362
    [Abstract] [Full Text] [Related]

  • 4. Low molecular weight heparins--state-of-the-art and unsolved issues.
    Breddin HK.
    Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S17-9. PubMed ID: 8180324
    [Abstract] [Full Text] [Related]

  • 5. [Low molecular weight heparins].
    Kher A, Bara L, Samama M.
    Pathol Biol (Paris); 1986 Jan; 34(1):61-9. PubMed ID: 3517772
    [Abstract] [Full Text] [Related]

  • 6. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
    Fareed J, Jeske W, Fareed D, Clark M, Wahi R, Adiguzel C, Hoppensteadt D.
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
    [Abstract] [Full Text] [Related]

  • 7. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
    Barrowcliffe TW, Thomas DP.
    Acta Chir Scand Suppl; 1988 Oct; 543():57-64. PubMed ID: 2847459
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
    Momi S, Nasimi M, Colucci M, Nenci GG, Gresele P.
    Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
    [Abstract] [Full Text] [Related]

  • 12. [Current status of low molecular weight heparin].
    Maillet P.
    Phlebologie; 1992 Mar; 45(2):179-83. PubMed ID: 1326773
    [Abstract] [Full Text] [Related]

  • 13. [Efficacy of a very low molecular weight heparin fragment (CY 222) compared to standard heparin in patients with deep venous thrombosis. A randomized study].
    Faivre R, Neuhart E, Kieffer Y, Bassand JP, Maurat JP.
    J Mal Vasc; 1987 Mar; 12 Suppl B():145-6. PubMed ID: 2834488
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Low-molecular-weight heparins and angiogenesis.
    Norrby K.
    APMIS; 2006 Feb; 114(2):79-102. PubMed ID: 16519745
    [Abstract] [Full Text] [Related]

  • 18. Why low molecular weight heparin?
    Mammen EF.
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():1-4. PubMed ID: 1962897
    [Abstract] [Full Text] [Related]

  • 19. [Practical use of low molecular weight heparins in angiology].
    Plettner JL.
    J Mal Vasc; 1991 Oct; 16(4):398-401. PubMed ID: 1665170
    [Abstract] [Full Text] [Related]

  • 20. An overview of clinical trials of low molecular weight heparin fractions.
    Levine MN, Hirsh J.
    Acta Chir Scand Suppl; 1988 Oct; 543():73-9. PubMed ID: 2847461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.